"Gout" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of URIC ACID calculi.
| Descriptor ID |
D006073
|
| MeSH Number(s) |
C05.550.114.423 C05.550.354.500 C05.799.414 C16.320.565.798.368 C18.452.648.798.368
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gout".
Below are MeSH descriptors whose meaning is more specific than "Gout".
This graph shows the total number of publications written about "Gout" by people in this website by year, and whether "Gout" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gout" by people in Profiles.
-
Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Risk of Venous Thromboembolism With Gout Flares. Arthritis Rheumatol. 2023 09; 75(9):1638-1647.
-
Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA. 2022 08 02; 328(5):440-450.
-
Abhishek A, Cipolletta E, Nakafero G, Avery AJ, Mamas M, Tata LJ. Serum urate outcomes of treat-to-target urate lowering treatment: results of a nationwide cohort study from 1997 to the COVID-19 pandemic using data from the Clinical Practice Research Datalink. Ann Rheum Dis. 2022 Dec; 81(12):1768-1769.
-
Abhishek A, Tata LJ, Mamas M, Avery AJ. Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021. Ann Rheum Dis. 2022 06; 81(6):898-899.
-
Kaul S, Gupta M, Bandyopadhyay D, Hajra A, Deedwania P, Roddy E, Mamas M, Klein A, Lavie CJ, Fonarow GC, Ghosh RK. Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. Am J Cardiovasc Drugs. 2021 Sep; 21(5):499-512.
-
Jutkowitz E, Alarid-Escudero F, Choi HK, Kuntz KM, Jalal H. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis. Pharmacoeconomics. 2017 Oct; 35(10):1073-1085.
-
Jutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017 04; 46(5):594-600.
-
Qaseem A, Harris RP, Forciea MA. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 03; 166(1):58-68.
-
Qaseem A, McLean RM, Starkey M, Forciea MA. Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 03; 166(1):52-57.
-
George M, Pullman-Mooar S, Hussain F, Schumacher HR. Evaluating appropriate use of prophylactic colchicine for gout flare prevention. Arthritis Care Res (Hoboken). 2014 Aug; 66(8):1258-62.